Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 10:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 156 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Lubricating Eye Drops Clear all
Not listed Not applicable Interventional Accepts healthy volunteers

Meibomian Gland Probing in the Sub-Acute Phase of Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis

NCT05145959
View directory record Official record
Conditions
Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses, Ocular Surface Disease, Meibomitis, Meibomian Gland Dysfunction, Dry Eye
Interventions
Maskin Probe
Device
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 5, 2021 · Synced Sep 7, 2026, 10:53 AM EDT
Withdrawn Phase 4 Interventional

A Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis®

NCT02028312
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Loteprednol etabonate, Artificial Tears, Restasis
Drug
Lead sponsor
Edward Holland, MD
Other
Eligibility
21 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Edgewood, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Sep 7, 2026, 10:53 AM EDT
Recruiting Phase 4 Interventional

The Effects of 3% Trehalose Ophthalmic Solution on Corneal Epithelial Barrier Function

NCT06655441
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
3% trehalose
Drug
Lead sponsor
Southern California College of Optometry at Marshall B. Ketchum University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Fullerton, California
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 7, 2026, 10:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Extended Tear Film Break Up Time (TFBUT) With an Ocular Emulsion

NCT01368198
View directory record Official record
Conditions
Dry Eye
Interventions
Systane Balance Lubricating Eye Drops, OPTIVE™
Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Feb 1, 2012 · Synced Sep 7, 2026, 10:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Tear Lipid Layer Thickness Changes With Use of Emollient and Non-Emollient Eye Drops

NCT03706443
View directory record Official record
Conditions
Dry Eye Syndromes, Keratoconjunctivitis Sicca, Lacrimal Apparatus Diseases, Keratoconjunctivitis, Eye Diseases, Keratitis, Corneal Disease, Ophthalmic Solution
Interventions
Systane Complete, Systane Ultra
Other
Lead sponsor
Ohio State University
Other
Eligibility
30 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 22, 2019 · Synced Sep 7, 2026, 10:53 AM EDT
Completed Phase 1 Interventional

The Pathophysiology of Orthostatic Hypotension

NCT00748059
View directory record Official record
Conditions
Autonomic Nervous System Diseases, Orthostatic Hypotension, Dopamine Beta-Hydroxylase Deficiency, Orthostatic Intolerance
Interventions
Standing or upright tilt, Microneurography, QSweat, neck cuff stimulation, phenylephrine,isoproterenol,nitroprusside,propranolol,edrophonium,atropine,tyramine, clonidine,yohimbine,metoclopramide,alpha-methyldopa, BodPod, Eye exam, Sleep study, Pain response testing, Metabolic chamber, Brain function studies, Bicycle Exercise Test
Procedure · Device · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
12 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Sep 7, 2026, 10:53 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

ACCURATE Study for Subjects With Dry Eyes

NCT04237012
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Dextenza 0.4Mg Intracanalicular Insert, Over the counter Artificial tears
Drug · Other
Lead sponsor
The Eye Centers of Racine and Kenosha
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Racine, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 28, 2024 · Synced Sep 7, 2026, 10:53 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Artificial Tears, Tear Lipids and Tear Film Dynamics

NCT05705518
View directory record Official record
Conditions
Dry Eye
Interventions
Systane Complete PF, Refresh Relieva PF, Refresh Optive Mega-3 PF, CVS Health Lubricant Eye Drop (PG 0.6%)
Drug
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Sep 7, 2026, 10:53 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Artificial Tears to Prevent Nasolacrimal Duct Obstruction in Patients Treated With Radioactive Iodine for Thyroid Cancer

NCT05999630
View directory record Official record
Conditions
Nasolacrimal Duct Obstruction, Thyroid Cancer
Interventions
Artificial Tears Methylcellulose
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Sep 7, 2026, 10:53 AM EDT
Terminated Not applicable Interventional Results available

Evaluating the Use of ProKera Plus® in the Management of Bacterial Corneal Ulcers

NCT04850313
View directory record Official record
Conditions
Bacterial Corneal Ulcer
Interventions
ProProKera Plus®
Device
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Sep 7, 2026, 10:53 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Tear Lipid Layer Thickness With Emollient Eye Drops

NCT03380624
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Refresh Optive, Refresh Optive MEGA-3
Drug
Lead sponsor
Ohio State University
Other
Eligibility
30 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Sep 7, 2026, 10:53 AM EDT
Withdrawn Phase 4 Interventional

Tear Film Markers in Dry Eye Syndrome

NCT04515329
View directory record Official record
Conditions
Dry Eye
Interventions
Cyclosporine, Artificial tear
Drug
Lead sponsor
Vishal Jhanji
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 17, 2023 · Synced Sep 7, 2026, 10:53 AM EDT
Not listed Phase 2Phase 3 Interventional

Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Previously Untreated Corneal Ulcers

NCT05255107
View directory record Official record
Conditions
Keratitis, Corneal Ulcer
Interventions
Standard of Care Therapy + CXL + Riboflavin 0.23% L Solution, Standard of Care Therapy + Sham CXL + Artificial Tears
Combination Product · Other
Lead sponsor
Peschke GmbH
Industry
Eligibility
18 Years and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
12
States / cities
Littleton, Colorado • Fort Myers, Florida • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Sep 7, 2026, 10:53 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Carboxymethylcellulose Artificial Tears on the Eye Microbiome

NCT05292755
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Carboxymethylcellulose (CMC) Artificial Tears, Preservative-free, CMC-free Artificial Tears (control)
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced Sep 7, 2026, 10:53 AM EDT
Recruiting Phase 3 Interventional

Parasitic Ulcer Treatment Trial

NCT06213649
View directory record Official record
Conditions
Acanthamoeba Keratitis
Interventions
Polyhexamethylene biguanide (PHMB), Topical corticosteroid, Topical placebo
Drug · Other
Lead sponsor
Jeremy Keenan, MD, MPH
Other
Eligibility
8 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
13
States / cities
San Francisco, California • Aurora, Colorado • Gainesville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 7, 2026, 10:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study to Evaluate a Contact Lens Lubricating and Rewetting Drop

NCT01267656
View directory record Official record
Conditions
Dry Eye
Interventions
Lubricating and Rewetting Drops, AMO Blink Contacts Lubricant Eye Drops
Device
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 29, 2020 · Synced Sep 7, 2026, 10:53 AM EDT
Not yet recruiting Phase 4 Interventional

Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery)

NCT07048886
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Rocklatan (netarsudil 0.02% and latanoprost 0.005%), Systane
Drug
Lead sponsor
Center for Sight Las Vegas
Other
Eligibility
40 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Sep 7, 2026, 10:53 AM EDT
Completed Not applicable Interventional

Study of Efficacy and Tolerability of SYSTANE Complete in Patients With Dry Eye Disease

NCT03492541
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Propylene glycol-based eye drops
Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Kansas City, Missouri • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Sep 7, 2026, 10:53 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

An Observational, Qualitative Study Assessing Eye Drop Administration

NCT05307081
View directory record Official record
Conditions
Ocular Injury
Interventions
Artificial Tears
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced Sep 7, 2026, 10:53 AM EDT
Terminated Not applicable Interventional Results available

Timolol Eye Drops in the Treatment of Acute Migraine Headache

NCT02630719
View directory record Official record
Conditions
Migraine
Interventions
Timolol eye drops, Artificial tears
Drug
Lead sponsor
University of Missouri, Kansas City
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Sep 7, 2026, 10:53 AM EDT
Completed Phase 4 Interventional Results available

Control of Pain in Intravitreal Injections Using Topical NSAIDs

NCT04343222
View directory record Official record
Conditions
Intravitreal Injections, IVI
Interventions
Bromfenac, Artificial tears
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 11, 2023 · Synced Sep 7, 2026, 10:53 AM EDT
Completed Not applicable Interventional

Evaluation of the Tolerability and Efficacy of CWT-f-002 Lubricant Eye Drops

NCT05660681
View directory record Official record
Conditions
Dry Eye Disease
Interventions
glycerin 0.7%/PEG 400 0.3%, polyethylene glycol 400 0.4%/propylene glycol 0.3%
Drug
Lead sponsor
Calm Water Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 7, 2026, 10:53 AM EDT
Completed Not applicable Interventional Results available

Reducing Adenoviral Patient Infected Days

NCT02472223
View directory record Official record
Conditions
Conjunctivitis, Adenoviral Conjunctivitis
Interventions
Betadine 5%, Artificial Tears
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Sep 7, 2026, 10:53 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis

NCT01456780
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Posterior Blepharitis
Interventions
Loteprednol/tobramycin, Loteprednol, B+L Advanced Eye Relief Lubricant Drop
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Sep 7, 2026, 10:53 AM EDT